This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the recent data presented at ASCO from the Phase 3 BREAKWATER clinical trial of BRAFTOVI (encorafenib) as a treatment for metastatic colorectal cancer.
Ticker(s): PFEWho's the expert?
Institution: University of Colorado Hospital
- Medical oncologist at UCHealth University of Colorado Hospital, specializing in breast cancer treatment and immunotherapy research.
- Principal investigator for clinical trials, advancing anti-endocrine therapies and novel vaccines for breast cancer and melanoma.
- Professor at the University of Colorado Denver, authoring over 200 peer-reviewed publications in oncology journals.
Interview GoalTo discuss the current standard of care and the potential of BRAFTOVI (encorafenib) as a combination therapy for the treatment of metastatic colorectal cancer.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
